Form 8-K - Current report:
SEC Accession No. 0001628280-24-041646
Filing Date
2024-10-01
Accepted
2024-10-01 07:10:25
Documents
17
Period of Report
2024-10-01
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K amrx-20241001.htm   iXBRL 8-K 27734
2 EX-99.1 amrxmetserapr_vfinal.htm EX-99.1 9713
6 amrxmetserapr_vfinal001.jpg GRAPHIC 267729
7 amrxmetserapr_vfinal002.jpg GRAPHIC 305319
8 amrxmetserapr_vfinal003.jpg GRAPHIC 33645
  Complete submission text file 0001628280-24-041646.txt   1002882

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT amrx-20241001.xsd EX-101.SCH 1995
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT amrx-20241001_lab.xml EX-101.LAB 21885
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT amrx-20241001_pre.xml EX-101.PRE 12599
19 EXTRACTED XBRL INSTANCE DOCUMENT amrx-20241001_htm.xml XML 2729
Mailing Address 400 CROSSING BOULEVARD 3RD FLOOR BRIDGEWATER NJ 08807
Business Address (908) 947-3120
Amneal Pharmaceuticals, Inc. (Filer) CIK: 0001723128 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38485 | Film No.: 241341299
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)